Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema
- PMID: 38126502
- PMCID: PMC10965002
- DOI: 10.36141/svdld.v40i4.14433
Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema
Abstract
Background and aim: There are many epidemiological pieces of evidence that show combined pulmonary fibrosis and emphysema (CPFE) patients have an increased risk of lung cancer. We conducted a systematic review of all published data to define the characteristics and treatments of lung cancer that develops in CPFE by performing a meta-analysis.
Methods: Databases(including PubMed, Medline, CNKI, VIP, etc.) were searched to find original articles that related to lung cancer in CPFE(CPFE-LC) patients and a meta-analysis was used to analyze the included 15 articles. Stata17.0 software was performed for this meta-analysis.
Results: Fifteen original studies that assessed 5933 patients were included in this meta-analysis. In the pooled data, people with CPFE-LC were elderly(70.58 years) and heavy smokers( 0.959, 45.793 pack-years), with a male predominance(0.959). Most lung cancer in CPFE was located in the lower lobe(0.533) and obvious areas of pulmonary fibrosis(0.516). Highest prevalence of cellular subtypes of lung cancer in CPFE was squamous carcinoma(SQCC, 0.437) and chemotherapy was the main treatment(0.387). The mortality rate was 0.720(95%CI: 0.657-0.783) and the 5-year survival rate was 0.250(95%CI: 0.133-0.368). The main cause of death was infection(0.268) and respiratory failure was the main cause of death after surgery(0.392).
Conclusions: Lung cancer in CPFE, most commonly SQCC, presents in elderly heavy smokers with a male, located in the lower lobe of the lung and the areas of fibrosis predominance. Chemotherapy is the main treatment and the optimal treatment remains to be explored.
Conflict of interest statement
Each author declares that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangement, etc.) that might pose a conflict of interest in connection with the submitted article.
Figures








References
-
- Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med. 1990;84(5):365–9. doi: 10.1016/s0954-6111(08)80070-4. - PubMed
-
- Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–93. doi: 10.1183/09031936.05.00021005. - PubMed
-
- Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. Curr Opin Pulm Med. 2012;18(5):418–27. doi: 10.1097/MCP.0b013e328356803b. - PubMed
-
- Roshan R, Guptal M, Kulshrestha R, Menon B, Chhabra SK. Combined pulmonary fibrosis and emphysema in a welder. Monaldi Arch Chest Dis. 2012;77(1):26–8. doi: 10.4081/monaldi.2012.164. - PubMed
LinkOut - more resources
Full Text Sources